

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2020 (02.01.2020)



(10) International Publication Number
WO 2020/006092 A1

(51) International Patent Classification:

A61K 9/70 (2006.01) A61K 47/38 (2006.01)
A61K 31/4174 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2019/039268

(22) International Filing Date:

26 June 2019 (26.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/690,407	27 June 2018 (27.06.2018)	US
62/693,726	03 July 2018 (03.07.2018)	US
62/767,422	14 November 2018 (14.11.2018)	US
62/787,649	02 January 2019 (02.01.2019)	US
62/798,842	30 January 2019 (30.01.2019)	US
62/849,747	17 May 2019 (17.05.2019)	US

(71) Applicants: **BIOXCEL THERAPEUTICS, INC.** [US/US]; 555 Long Wharf Drive, New Haven, Connecticut 06511 (US). **ARX, LLC** [US/US]; 400 Seaks Run Road, Glen Rock, Pennsylvania 17327 (US).

(72) Inventors: **KAKUMANU, Vasukumar**; D. No.: 16-18-27, Burlevar Street, Old Guntur, Guntur 522001 (IN). **YOCCA, Frank**; c/o BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, Connecticut 06511 (US). **LATHIA, Chetan Dalpatbhai**; 10 Nettleton Drive, Woodbridge, Connecticut 06525 (US). **HANLEY, David Christian**; 86 Whisconier Rd, Brookfield, Connecticut 06804 (US). **BARNHART, Scott David**; 1820 Shawan Lane, York, Pennsylvania 17406 (US).

(74) Agent: **BROWN, Fraser D.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, N.W., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):


ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM

FIG. 1: shows cross-sectional (side) view and area (top) view of a monolithic matrix film



(57) Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by trans mucosal delivery of the active agent.

WO 2020/006092 A1